Motif Bio plc Warrants to Purchase ADRs
MTFBW
MTFBW was delisted on the 16th of December, 2019.
3 hedge funds and large institutions have $1.76M invested in Motif Bio plc Warrants to Purchase ADRs in 2018 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
4% more capital invested
Capital invested by funds: $1.7M → $1.76M (+$60K)
0% more funds holding
Funds holding: 3 → 3 (0)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$739 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Invesco
Atlanta,
Georgia
| $1.39M | – | – | – |
|
|
SGCM
2
Sand Grove Capital Management
London,
United Kingdom
| $364K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $3K | -$739 | -290 | -21% |
|
MTFBW Hedge Fund Activity: Q3 2018 in Review
3 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Motif Bio plc Warrants to Purchase ADRs (MTFBW) for Q3 2018, worth a combined $1.76M — up 3.5% from $1.7M a quarter earlier.
Fund positioning in MTFBW was balanced in Q3 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $739.
- 3 institutional investors held Motif Bio plc Warrants to Purchase ADRs (MTFBW) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $1.76M of Motif Bio plc Warrants to Purchase ADRs stock for Q3 2018, up 3.5% quarter-over-quarter.
- 0 funds opened new Motif Bio plc Warrants to Purchase ADRs positions in Q3 2018 and 0 closed out.
- The largest Motif Bio plc Warrants to Purchase ADRs seller in Q3 2018 was UBS Group, an estimated $739 sold.
Based on aggregated 13F filings for Q3 2018.